Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2016 1
2017 2
2018 5
2019 2
2020 9
2021 7
2022 8
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M, Cuppens K, Plönes T, Wiesweg M, Du Pont B, Hegedus B, Köster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lähnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Schuler M, et al. Among authors: wiesweg m. Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965-0. Online ahead of print. Nat Med. 2024. PMID: 38689060
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust DE, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck TR, Griesinger F, Jakopovic M, Hochmair MJ, Wermke M. Illini O, et al. Among authors: wiesweg m. Int J Mol Sci. 2024 Apr 3;25(7):3992. doi: 10.3390/ijms25073992. Int J Mol Sci. 2024. PMID: 38612799 Free PMC article.
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, Lueong S, Metzenmacher M, Herold T, Zaun G, Laue K, Drzezga A, Theegarten D, Nensa F, Wolf J, Herrmann K, Wiesweg M. Schuler M, et al. Among authors: wiesweg m. J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979. Online ahead of print. J Nucl Med. 2024. PMID: 38575188
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M, Pöttgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, Metzenmacher M, Aigner C, Bölükbas S, Gauler T, Eberhardt WEE, Forsting M, Herrmann K, Theegarten D, Darwiche K, Jendrossek V, Stuschke M, Schuler M. Guberina M, et al. Among authors: wiesweg m. Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174. Cancers (Basel). 2024. PMID: 38539510 Free PMC article.
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G, Borchert S, Metzenmacher M, Lueong S, Wiesweg M, Zaun Y, Pogorzelski M, Behrens F, Schildhaus HU, Virchow I, Kasper S, Schuler M, Theurer S, Liffers S. Zaun G, et al. Among authors: wiesweg m. Eur J Cancer. 2024 Mar;200:113540. doi: 10.1016/j.ejca.2024.113540. Epub 2024 Jan 26. Eur J Cancer. 2024. PMID: 38316065 Free article.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wesseler C, Waller CF, Kauffmann-Guerrero D, Stenzinger A, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, Frost N; National Network Genomic Medicine Lung Cancer (nNGM) Collaborator Group. Bischoff P, et al. Among authors: wiesweg m. J Thorac Oncol. 2023 Dec 13:S1556-0864(23)02423-1. doi: 10.1016/j.jtho.2023.12.015. Online ahead of print. J Thorac Oncol. 2023. PMID: 38096950 Free article.
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
Kersting D, Sandach P, Sraieb M, Wiesweg M, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Nader M, Hamacher R, Fendler WP, Wienker J, Eberhardt WEE, Schuler M, Herrmann K, Hautzel H. Kersting D, et al. Among authors: wiesweg m. J Nucl Med. 2023 Oct;64(10):1540-1549. doi: 10.2967/jnumed.123.265664. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474272
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.
Zaun G, Weber M, Metzenmacher M, Wiesweg M, Hilser T, Zaun Y, Liffers S, Pogorzelski M, Virchow I, Eberhardt W, Theurer S, Sabbah TA, Reissig TM, Stuschke M, Kürten C, Hussain T, Lang S, Kasper S, Fendler WP, Herrmann K, Schuler M. Zaun G, et al. Among authors: wiesweg m. J Nucl Med. 2023 Aug;64(8):1191-1194. doi: 10.2967/jnumed.122.265161. Epub 2023 Jun 15. J Nucl Med. 2023. PMID: 37321823
Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.
Warnecke E, Salvador Comino MR, Kocol D, Hosters B, Wiesweg M, Bauer S, Welt A, Heinzelmann A, Müller S, Schuler M, Teufel M, Tewes M. Warnecke E, et al. Among authors: wiesweg m. Cancers (Basel). 2023 Jun 1;15(11):3029. doi: 10.3390/cancers15113029. Cancers (Basel). 2023. PMID: 37296991 Free PMC article.
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, Metzenmacher M, Schmid KW, Herold T, Schildhaus HU, Darwiche K, Aigner C, Stuschke M, Laue K, Zaun G, Kasper S, Hense J, Sebastian M, Schuler M, Pogorzelski M. Kraskowski O, et al. Among authors: wiesweg m. J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18. J Cancer Res Clin Oncol. 2023. PMID: 37198447 Free PMC article.
44 results